Clinical Trial Update: Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial [Phase 2]

View source ↗

Summary

Phase II neoadjuvant trial assessing pyrotinib in combination with chemotherapy for HER2-low-expressing, hormone receptor-positive breast cancer; currently acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Low-expressing Breast Cancer

Drugs mentioned

• Pyrotinib (brand name Tyvyt) (pyrotinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer, HER2-low-expressing Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING